This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design.
Part 1 of the book set covers these topics:
- Heterocyclic anticancer compounds derived from natural sources with their mechanism of action
- The role of terpenoids as anticancer compounds: an insight into prevention and treatment
- Recent advances in synthesis and anticancer activity of benzothiazole hybrids as anticancer agents
- Structure-activity relationship studies of novel hybrid quinoline and quinolone derivatives as anticancer agents
- Tetrazoles: structure and activity relationship as anticancer agents
- Progress in nitrogen and oxygen-based heterocyclic compounds for their anticancer activity: an update (2017-2020)
Table of Contents
Chapter 1 Heterocyclic Anti-Cancer Compounds Derived From Natural Sources With Their Mechanism Of Action- Introduction
- Deaths From Cancer Are A Global Threat
- The Anti-Cancer Natural Compounds' Rationale
- Mechanisms Of Action Of Anti-Cancer Compounds
- Inhibition Of Angiogenesis
- Induction Of Apoptosis
- Induction Of Autophagy
- Arresting Cell Cycle Kinetics
- Modulation Of Dna Methylation
- Modulation Of Endoplasmic Reticulum Stress
- Regulation Of Inflammation
- Reduction Of Invasion, Migration, And Metastasis
- Reduction Of Proliferation Of Cancer Cells
- Targeting Cancer Stem Cells
- Anti-Cancer Natural Compounds
- Potential Anti-Cancer Compounds From Plant Sources
- Dna Topoisomerase Inhibitors
- Mitotic Inhibitors
- Potential Anti-Cancer Compounds From Microbial Sources
- Dna Intercalating Agents
- Histone Deacetylase Inhibitors
- Mtor Inhibitors
- Potential Anti-Cancer Compounds From Marine Sources
- Mitotic Inhibitors
- Dna Minor-Groove Alkylators
- Introduction Of Natural Anti-Cancer Compounds In Clinical
- Trials (Drug Development)
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
- Introduction
- Hemiterpenoids
- Monoterpenoids
- Sesquiterpenoids
- Diterpenoids
- Sesterterpenoids
- Triterpenoids
- Tetraterpenoids
- Analogs Of Terpenoids
- Structure Modification In Terpenoids
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgement
- References
- Introduction
- Benzothiazole Chemistry And Nomenclature
- Synthetic Methodology
- Biological Activities
- Benzothiazole And Its Derivatives As Anticancer Agents
- Antimitotic Agent
- A Tyrosine Kinase Inhibitor
- Epidermal Growth Factor Receptor (Egfr) Inhibitors
- A Bcr-Abl Kinase Inhibitor
- Pi3K/Akt/Mtor Enzyme Inhibitors
- Inhibitors Of The Braf Enzyme
- Hdac Inhibitor
- Dna-Topoisomerase Inhibitor
- Aurora Kinase Inhibitors
- Inhibitor Of Monoacylglycerol Lipase
- Inhibitors Of The Nedd8 Activating Enzyme
- Inhibitors Of Heat Shock Protein 90
- Recently Developed Benzothiazole Analogs As An Anticancer
- Agent
- Patent Granted On Benzothiazole Scaffold
- Role Of Benzothiazole-Bearing Clinical Trial Drugs In The Future
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgement
- References
- Introduction
- Quinoline-Coumarin/Chrome Hybrids
- Quinoline-Azole Hybrids
- Quinoline-Pyrazole Hybrids
- Quinoline-Oxazole Hybrids
- Quinoline-Oxadiazole Hybrids
- Quinoline-Triazole Hybrids
- Quinoline-1,2,3-Triazole Hybrids
- Quinoline-1,2,4-Triazole Hybrids
- Quinoline-Tetrazole Hybrids
- Quinoline-Piperazine Hybrids
- Quinoline-Chalcone Hybrids
- Quinoline-Thiophene Hybrids
- Quinoline-Galactose Hybrids
- Miscellaneous Quinoline Hybrids
- Quinolone Derivatives As Anticancer Agents
- Pyrano[3,2-C]Quinolone Analogs As Anticancer Agents
- Ciprofloxacin Hybrids As Anticancer Agents
- Quinolone-Benzimidazole Hybrids As Anticancer Agents
- Ferrocene-Quinolone Hybrids As Anticancer Agents
- Carbohydrate Fused Pyrano[3,2-C]Quinolone Hybrids As Anticancer Agents
- Oxindole-Quinolone Hybrids As Anticancer Agents
- Fluoroquinolone-Boron Complexes As Anticancer Agents
- Quinolone-Pyrimidine Hybrids
- Benzo[D]Thiazolyl Substituted-2-Quinolone Hybrids As Anticancer Agents
- Indeno-Quinoxaline Pyrrolidine Quinolone Hybrids As Anticancer Agents
- Quinolone-1,5-Benzothiazepines Hybrids As Anticancer Agents
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
- Introduction
- Biological Background Of Tetrazole Nucleus
- Synthesis Of Tetrazoles
- Other Methodologies Of Synthesis
- Tetrazole Containing Compounds With Anti-Cancer Activity
- Structure And Activity Relationship Studies
- Mechanism Of Action
- Protein Arginine Methyl Transferase 1 Inhibitors
- Pad (Protein Arginine Deiminases) Inhibitors
- Ki-67 Expression Suppression
- Efflux Pump Inhibiton
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
- Introduction
- Acridine
- Chemistry Of Acridine
- Anticancer Activity Of Acridine Derivatives
- Benzimidazole
- Chemistry Of Benzimidazole
- Anticancer Activity Of Benzimidazole Derivatives
- Oxadiazole
- Chemistry Of Oxadizole
- Anticancer Activity Of Oxadiazole Derivatives
- Isoxazole
- Chemistry Of Isoxazole
- Anticancer Activity Of Isoxazole Derivatives
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgement
- References
- Subject Index
Author
- Rajesh Kumar Singh
